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Abstract
Background/Aims: Chronic kidney disease and, specifically, diabetic kidney disease, is 
among the fastest increasing causes of death worldwide. A better understanding of the 
factors contributing to the high mortality may help design novel monitoring and therapeutic 
approaches. CXCL16 is both a cholesterol receptor and a chemokine with a potential role in 
vascular injury and inflammation. We aimed at identifying predictors of circulating CXCL16 
levels in diabetic patients with chronic kidney disease. Methods: We have now studied plasma 
CXCL16 in 134 European patients with diabetic kidney disease with estimated glomerular 
filtration rate (eGFR) categories G1-G4 and albuminuria categories A1-A3, in order to identify 
factors influencing plasma CXCL16 in this population. Results: Plasma CXCL16 levels were 
4.0±0.9 ng/ml. Plasma CXCL16 increased with increasing eGFR category from G1 to G4 (that is, 
with decreasing eGFR values) and with increasing albuminuria category. Plasma CXCL16 was 
higher in patients with prior cardiovascular disease (4.33±1.03 vs 3.88±0.86 ng/ml; p=0.013). 
In multivariate analysis, eGFR and serum albumin had an independent and significant negative 
correlation with plasma CXCL16. Conclusion: In diabetic kidney disease patients, GFR and 
serum albumin independently predicted plasma CXCL16 levels.
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IntroductionChronic Kidney Disease is the non-transmissible cause of death that increased the most worldwide over the past 20 years [1]. The increasing incidence of diabetic kidney disease is one of the key drivers of this trend. Cardiovascular disease (CVD) is one of the top causes of death in CKD patients [2]. However, the pathogenic mechanisms linking CKD with CVD remain poorly understood and thus, therapy is unsatisfactory. Chronic low grade systemic 
inflammation and lipid abnormalities are thought to play a role. Among inflammatory fac-tors, chemokine (C-X-C) ligand 16 (CXCL16) is a small cytokine and cell surface receptor be-longing to the CXC chemokine family that has been linked to lipid metabolism and to vascular disease [3-5].CXCL16 is synthesized as a transmembrane molecule that is expressed as a cell sur-face-bound molecule, as well as a soluble chemokine [6]. CXCL16 interacts with the CXC-chemokine receptor CXCR6 in leukocytes and other cells promoting chemotaxis (solu-ble CXCL16) or cell adhesion (membrane-bound CXCL16) [7]. In addition, CXCL16 was orig-inally described as a scavenger receptor for phosphatidylserine and oxidized low-density li-
poprotein (oxLDL) and termed SR-PSOX [8]. Inflammatory cytokines such as interferon gam-ma (IFNγ) and tumor necrosis factor alpha (TNFα) promote CXCL16 expression [7]. CXCL16 has been implicated in the pathogenesis of vascular, kidney and lung injury. Upon cleavage of the mucin-like stalk, the CXCL16 chemokine is released and functions as a chemoattractant for CXCR6+ T, natural killer (NK), B, and dendritic cells [9-12].CXCL16 is expressed in mouse and human injured kidneys and coronary and carotid 
atherosclerotic lesions, colocalizing with tubular cells, infiltrating macrophages, lipid-laden intimal macrophages and smooth muscle cells [13-15]. However, studies evaluating soluble CXCL16 as a potential biomarker of coronary artery disease have been inconsistent [16, 17]. 
A polymorphic variant of CXCL16 was associated with increased coronary artery stenosis in post-infarction patients [18]. 
The high stability of CXCL16 (e.g., little circadian variation, minor influence of food intake, and little variation after freeze and thaw cycle) further supports a potential role of CXCL16 as a biomarker in clinical samples [19]. High circulating CXCL16 levels within 24 hours of admission for myocardial ischemia predicted long-term mortality and congestive heart failure development [19]. However decreased or increased CXCL16 levels in both stable 
and unstable angina were reported in different studies [17, 20, 21]. A potential explanation for this variability is the presence of factors that are associated to both increased CXCL16 
levels and adverse cardiovascular outcomes, as might be CKD. A majority of patients with 
ischemic heart disease may have reduced glomerular filtration rate (GFR): 76% had eGFR 
category G 2-5 in a recent prospective cohort [22]. In this regard, serum CXCL16 levels were 
significantly increased in CKD and gout subjects [23, 24]. These findings suggest that CXCL16 
may be a marker of renal disease. No significant differences in serum CXCL16 levels between healthy and type 2 diabetes mellitus (DM) subjects were found. However, CXCL16 levels were higher in Chinese patients with diabetic kidney disease (DKD) than in CKD patients without diabetes [24]. In this regard, there are differences 
between Asians and Caucasians in terms of prevalence of proteinuric DKD (higher in Asians), 
progression of CKD (faster in Asians) and CKD-associated mortality (lower in Asians) [25, 26]. Thus, information derived from other ethnicities is required to better understand the predictors of CXCL16 levels in DKD.We have now explored the determinants of circulating CXCL16 levels in diabetic CKD patients in a European setting.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
id
ad
 A
ut
on
om
a 
de
 M
ad
rid
   
   
   
   
   
   
   
   
 
15
0.
24
4.
13
8.
20
3 
- 2
/2
/2
01
7 
1:
00
:0
6 
PM
 Kidney Blood Press Res 2016;41:663-671
DOI: 10.1159/000447935
Published online: September 26, 2016
© 2016 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 665
Elewa et al.: Circulating CXCL16 in Diabetic Kidney Disease
Material and Methods
Study population
The study was performed at Fundación Jiménez Díaz University Hospital—Autonomous University of Madrid and approved by the IIS-Fundacion Jimenez Diaz Ethics Committee. Before enrollment, the study was fully explained to all participating patients and an informed consent was signed. This cross-sectional observational study assessed baseline data from 134 Caucasian European diabetic patients with CKD. Patients not on dialysis attending the monographic outpatient diabetic kidney disease clinic were 
offered to participate. No limits were provided for estimated glomerular filtration rate (eGFR) or urinary 
albumin:creatinine ratio (UACR). The CKD-EPI formula was used for eGFR calculation [27]. Exclusion criteria were age under 18 years, positive serology for Hepatitis C Virus (HCV), Hepatitis B Virus surface 
Antigen (HbsAg) or Human Immunodeficiency Virus (HIV), being on dialysis or transplantation or refusal 
to participate or sign an informed consent. All individuals were subjected to a complete clinical history, including assessment of current pharmacological treatment, blood and urine analysis, and transthoracic echocardiogram. Plasma samples were obtained in a stable state, in the absence of superimposed 
inflammatory conditions beyond the systemic inflammation associated with diabetes, CKD or cardiovascular disease. Plasma samples were collected after a 12 h fast and immediately processed and frozen at 80ºC until 
use. Plasma CXCL16 was assessed by ELISA (R&D Systems, Minneapolis, USA). The limit of detection was 
0.017 ng/ml, and the coefficients of inter- and intra-assay variability were 9.6 % and 4.2 %.
Statistical MethodologyData analyses were performed using statistical software R version 3.0.1. Quantitative variables were 
described by mean and standard deviation or by median and inter-quartile ranges (IQR); 25% percentile 
and 75% percentile. Qualitative variables were described by frequency tables and contingency tables. Asso-ciations between quantitative and qualitative variables were assessed using Student’s t test or Mann-Whit-
ney test when comparing two groups, and ANOVA or Kruskal-Wallis test when comparing three or more 
groups. Correlations between quantitative variables were evaluated using Spearman correlation coefficient. In order to identify potential predictors of quantitative outcomes, multivariable linear regression models 
were fitted. Models were built using forward stepwise procedures in order to maximize R-Squared with the 
smallest number of predictor variables. The statistical significance of variables in the models was assessed 
by ANOVA test.
ResultsWe performed a cross-sectional analysis of baseline data from patients with diabetic CKD not on dialysis on regular follow-up visits in the diabetic nephropathy clinic at Fundación Jiménez Díaz University Hospital. Plasma CXCL16 was assessed in 134 patients; all of them 
were diabetic and most (130/134) had CKD (Table 1). Most patients were in eGFR category 
G3 (63/134, 47%). Mean age was 67.9±13.9 years and a majority was male (92/134, 69%). 
This population was borderline obese with mean BMI 29.7±4.2 kg/m2. 
Mean eGFR was 56.0±25.1 ml/min/1.73 m2 and the median (IQR) UACR was 123.6 
(27.1, 386.7). In 17 (13%) patients UACR was >1000 mg/g). All patients were on anti-
hypertensive agents and most on RAAS blockade (131, 98%), anti-platelet agents (90, 67%), 
oral hypoglycemic agents (84, 63%), insulin (90, 67%) and lipid lowering agent (113, 84%). 
Only 48 (36%) were on vitamin D or VDR activators, 12 (9%) on phosphate binders and 7 
(5%) on erythropoiesis stimulating agents. 
Mean±SD plasma CXCL16 levels were 4.0±0.9 ng/ml. We explored the association of plasma CXCL16 levels with clinical, echocardiogram, therapeutic and laboratory parameters. 
Plasma CXCL16 increased with increasing eGFR category (that is, with decreasing eGFR) 
(Figure 1) and with increasing UACR (Figure 2). Table 2 shows CXCL16 values according to 
GFR (G) and albuminuria (A) categories.
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Plasma CXCL16 was higher in patients with prior CVD 
(4.33 ±1.03 vs 3.88± 0.86 ng/ml; p=0.0132). The univariate analysis of plasma CXCL16 (ng/ml) with quantitative variables disclosed positive correlations between CXCL16 
and age, pulse pressure, UACR, serum phosphorus, alkaline phosphatase and intact PTH. CXCL16 had a negative correlation with diastolic blood 
pressure, eGFR, hemoglobin, serum total iron binding capacity, serum albumin, CO2, serum calcium, 1,25(OH)2D and folic acid (Figure 3) (Table 3). In multivariate analysis, 
eGFR and serum albumin remained independently 
and significantly negatively correlated with plasma CXCL16, 
while UACR was independently positively correlated with plasma CXCL16 when serum albumin was not part of the equation (Table 4). The best R squared obtained was 0.30.
Discussion
The main findings from this study are that in a Europe-an, non-dialysis DKD popula-
tion, eGFR and serum albumin were independent predictors 
Table 1. Patient characteristics (n=134 diabetic CKD patients). 
Quantitative data expressed as mean ±SD or median (interquar-tile range) as appropriate
Fig. 1. Plasma CXCL16 values ac-cording to estimated 
glomerular filtra-
tion rate (eGFR) G category. * p<0.05 
vs CKD category G1 and p<0.002 vs CKD 
categories G1+G2; ** p<0.01 vs stage 1 and p <0.0001 vs CKD categories 
G1+G2.
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of CXCL16 that to-
gether with UACR explain around 
30% of the vari-ability in CXCL16 levels. While in univariate analy-sis, higher CXCL16 levels were associ-ated with CVD and a number of other markers, these as-sociations were no 
longer significant 
when eGFR was in- Fig. 2. Plasma CXCL16 values according to UACR. * p <0.01 vs UACR <30 mg/g.
Table 2. Circulating CXCL16 levels (ng/ml) according to CKD G and A categories. Median [IQR] (n)
Fig. 3. Statistically significant uni-variate correlations with plasma 
CXCL16 that were also significant in at least some multivariate mod-
els. A) CXCL16 and estimated glo-
merular filtration rate (eGFR). B) 
CXCL16 and UACR. C) CXCL16 and serum albumin.
Table 3. Correlations between plasma CXCL16 (ng/ml) and quantitative variables in univar-iate analysis. Only statistically 
significant (p< 0.05) results are shown
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troduced in multivariate models. The strong association between eGFR and CXCL16 levels may underlie the disparate observations regarding the relationship between CXCL16 and CVD or outcomes.
Increasing CXCL16 levels with decreasing eGFR may represent an aspect of the systemic 
inflammation associated with uremia. Indeed, mean plasma CXCL16 levels were 4.0±0.9 ng/ml in European patients with DKD. This compares with previously reported mean values 
in Asia of 1.30±0.05 ng/ml for the general population, 2.65±0.11 ng/ml for CKD patients, 
3.04±0.16 ng/ml for DKD patients and 1.23±0.04 ng/ml for type 2 DM patients [28].In multiple regression analysis, the independent predictors of high plasma CXCL16 
were low eGFR and low serum albumin. Thus, a relationship was found between CXCL16 
and parameters of renal function (eGFR) and a marker of nutrition, serum albumin, that is 
also a negative acute phase reactant. UACR was also an independent predictor of plasma 
CXCL16 when adjusted for eGFR, but not when serum albumin was included in the equation, 
suggesting that UACR and serum albumin may represent, in part, different aspects of the same phenomenon. While high albuminuria will lead to low serum albumin levels, the fact that serum albumin is a stronger predictor suggests a further additional relationship 
between serum albumin and CXCL16. In this regard, CXCL16 is a promoter of inflammation and, as such, may contribute to lower serum albumin levels independently form proteinuria.
A study of 146 Chinese patients with CKD of diverse etiologies observed a correlation 
between plasma CXCL16 levels and eGFR [24]. A smaller study of 30 Chinese DKD patients 
disclosed that plasma CXCL16 levels were independently associated with eGFR and 
proteinuria and negatively correlated with serum albumin [28]. Thus, we have confirmed in 
a large White DKD population that eGFR and serum albumin are independent predictors of plasma CXCL16 levels across several ethnicities, while albuminuria has a milder association. In this regard, plasma CXCL16 was positively correlated with 24-hour urine protein but negatively correlated with serum albumin in 50 active nephrotic syndrome patients [29].
This study has established a correlation between decreased GFR and serum albumin and high circulating CXCL16 levels. This observational study can only be hypothesis generating. The clinical implications will depend on which hypothesis is correct, but may even include 
circulating CXCL16 being a target for therapy if experimental interventional studies confirm data suggesting a pathogenic role for CXL16 in kidney injury [5]. In this regard, several hypotheses may explain the relationship between parameters of kidney function and plasma 
CXCL16. The association between plasma CXCL16 and GFR may be related to either a low 
clearance of CXCL16 when renal function deteriorates or to the presence of inflammation in CKD. In this regard, it is not known how CXCL16 is cleared from the circulation. The fact that CXCL16 correlated with proteinuria in nephrotic syndrome suggests that circulating CXCL16 is not excreted in great amounts in urine or that synthesis is higher than potential urinary losses. Furthermore, there is also evidence that CXCL16 is expressed by injured tubular cells 
Table 4. Multivariate models for predictors of CXCL16 (ng/ml) levels
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in the course of acute or chronic interstitial inflammation, as that caused by proteinuria [13]. Thus, the kidney may be source of circulating CXCL16 in proteinuric nephropathies, 
especially if advanced to the point where GFR is decreased. Finally, there is experimental evidence that CXCL16 may cause glomerular injury, adding a further potential explanation between the observed association between circulating CXCL16 and markers of severity of kidney injury [5]. In this regard, CXCL16 is the main scavenger receptor for ox-LDL in human podocytes [30, 31].Some limitations should be acknowledged. Thus, as is the case for other cross-sectional studies, only one baseline determination is available, and variability of CXCL16 levels over time was not assessed. Furthermore, the number of sample was relatively small. 
Conclusion
In diabetic CKD patients, decreased GFR and serum albumin are independent predictors of circulating CXCL16 levels. However, plasma CXCL16 was not associated with CVD in multivariate analysis. Unraveling cause-and effect relationships for this observation may help guide therapy, since there is experimental evidence that kidney injury may increase CXCL16 levels and also that high CXCL16 levels may promote kidney injury. In this regard, the 
strong association between eGFR and CXCL16 levels may underlie the disparate observations regarding the relationship between CXCL16 and CVD or outcomes.
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